A clinical study of transdermal contraceptive patch in Thai adolescence women.
OBJECTIVE
To study cycle control, compliance and safety of a transdermal contraceptive patch in adolescent Thai women.


METHODS
Fifty-eight healthy women were assigned to receive 3 cycles of contraceptive patch (ethinyl estradiol 20 microg and norelgestromin 150 microg/day). All participants aged 16-20 years were invited to participate from the family planning clinic at King Chulalongkorn Memorial Hospital. Data were collected on adverse effects, perceived advantages and disadvantages, body weight, blood pressure, patch detachments and compliance. Data were analyzed using mean, percentage and student's t-test.


RESULTS
The participants' average age was 19.4 years, height 158.8 cm, weight 51.8 kg, BMI 20.8 Kg/m2. The most location of patch application was the abdomen and the most adverse event was breast tenderness (31.0%) followed by application site reaction, nausea vomiting and headache respectively. The breast symptom was mild in severity. The participants reported decrease in dysmenorrhea and shorter duration of bleeding. There were no significant changes in body weight and blood pressure. The improvement of their facial acne was reported. There were no pregnancies during use and the adhesion of the contraceptive patch is excellent. Partial patch detachment was reported in only 6.9%. No completed patch detachment was found.


CONCLUSIONS
The present study found an overall positive impression of a new transdermal contraceptive patch. The good compliance and few side effects were demonstrated. The adhesive patch contraceptive was excellent.
Piyasirisilp
Rachatapon
R
Department of Obstetric and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Taneepanichskul
Surasak
S
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001794:Blood Pressure; D001835:Body Weight; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004412:Dysmenorrhea; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D019304:Ethinyl Estradiol-Norgestrel Combination / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D009644:Norgestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010091:Oximes / Q000008:administration & dosage / Q000009:adverse effects; D013785:Thailand
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D010091:Oximes; D009644:Norgestrel; D004997:Ethinyl Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination; C449219:norelgestromin